Measuring antibodies in saliva is a useful and easy strategy to detect SARS-CoV-2 infections

A study, published in BMC Medicine, performed through the Kids Corona platform from Sant Joan de Déu in collaboration with ISGlobal, shows that measuring antibodies in saliva is a useful and easy strategy to detect SARS-CoV-2 infections.

  1. Two subtypes of retinoblastoma identified

    Researchers from the Institut de Recerca Sant Joan de Déu have collaborated in a study, published in Nature Communications, which has identified two subtypes of molecular retinoblastoma with different genomic, clinical and pathological features.

  2. Brown adipose tissue activity is higher in girls during the first year of life

    A team led by Dr Lourdes Ibáñez and Dr Francesc Villarroya, IRSJD researchers, publishes the first study that shows the very early appearance of differences in the activity of the brown adipose tissue between girls and boys

  1. Researchers discover new phenotypic characteristics in inherited disorders of neurotransmitter metabolism

    The study co-led by Dr Àngels Garcia-Cazorla, Institut de Recerca Sant Joan de Déu (IRSJD), has studied more than 270 patients with ultra-rare neuro-metabolic diseases to describe and evaluate their initial clinical and biochemical characteristics improve their diagnosis.

  2. Detecting long QT syndrome early could help reduce the impact of sudden infant death

    A team led by Dra. Georgia Sarquella (IRSJD) and Drs. Ramon Brugada and Oscar Campuzano (IDIBGI) provide new diagnostic measures to prevent sudden infant death from long QT syndrome.

  3. Dr. Lourdes Ibañez coordinates the European SPIOMET4HEALTH project: a new treatment for polycystic ovary syndrome in adolescents and young women

    Dr. Lourdes Ibañez, from the Institut de Recerca Sant Joan de Déu, coordinates the new European SPIOMET4HEALTH will test the efficacy of this new treatment for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young adult women, in a multi-centric phase II clinical trial.

  4. Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital

    Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.

  5. More than 6% of Europeans suffer from depression

    Dr. Antoni Serrano (Institut de Recerca Sant Joan de Déu) participates in a study led by King's College London and the Hospital del Mar Medical Research Institute where the prevalence of depression among the population of more than 27 European countries has been studied.

  6. Predicted prognosis of one type of childhood cancer by tumour engraftment in mice

    Researchers of the Institut de Recerca Sant Joan de Déu and the SJD Barcelona Children's Hospital have made public their ten-year experience with the development of animal models of paediatric sarcomas